DDrare: Database of Drug Development for Rare Diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
46	悪性関節リウマチ	1

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01374971 (ClinicalTrials.gov)	September 2011	14/6/2011	Rheumatoid Arthritis Treatment and Biopsy Study Assessing Certolizumab Pegol (Cimzia)	Open-Label Pre and Post Treatment Arthroscopic Synovial Biopsy Study for the Assessment of Certolizumab Pegol Immunomodulatory Synovial Effects on Select Biomarkers and Gene Expression	Rheumatoid Arthritis	Drug: Certolizumab Pegol (CZP);Procedure: Arthroscopic synovial tissue biopsy	Nathan Wei, MD, FACP, FACR:	University of California, San Diego	Completed	18 Years	N/A	All	12	Phase 3	United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT01374971
(ClinicalTrials.gov)

September 2011

14/6/2011

Rheumatoid Arthritis Treatment and Biopsy Study Assessing Certolizumab Pegol (Cimzia)

Open-Label Pre and Post Treatment Arthroscopic Synovial Biopsy Study for the Assessment of Certolizumab Pegol Immunomodulatory Synovial Effects on Select Biomarkers and Gene Expression

Rheumatoid Arthritis

Drug: Certolizumab Pegol (CZP);Procedure: Arthroscopic synovial tissue biopsy

Nathan Wei, MD, FACP, FACR:

University of California, San Diego

Completed

18 Years

N/A

All

Phase 3

United States